Trials / Not Yet Recruiting
Not Yet RecruitingNCT06142188
Relmacabtagene Autoleucel in Hematologic Malignancies
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Detailed description
The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion. The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice. No therapeutic intervention will be administered to patients in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Relmacabtagene Autoleucel | A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells |
Timeline
- Start date
- 2023-12-28
- Primary completion
- 2038-12-31
- Completion
- 2038-12-31
- First posted
- 2023-11-21
- Last updated
- 2023-11-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06142188. Inclusion in this directory is not an endorsement.